April 2010, Array BioPharma (ARRY) entered into a license agreement with Novartis (NVS) @Novartis which granted Novartis the exclusive worldwide right to develop and commercialize binimetinib, as well as other specified MEK inhibitors. March 2015, Array regained these rights and the 2010 License Agreement terminated on the Effective Date of the Binimetinib Agreement. January 2015, […]